Part one of a three-part series.
The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Currently in the form of apill, the compound was conceived by Vancouver, BC-based natural drug development companyFilament Health(OTC:FLHLF).
During the development process, questions arose:
- What exactly constitutes a dose when discussing a drug typically used within religious contexts?
- What's the need of the drug-induced trip experience (and the typical pre-trip nausea) for obtaining health benefits?
- How can Filament actually perform drug development tasks in a responsible manner facing ayahuasca's sacramental essence?
Login or create a forever free account to read this news
Sign up/Log in